Abstract
Effective treatments are not yet available for neurodegenerative diseases, which are rapidly increasing in number as life spans in many countries continue to lengthen. Neurodegenerative diseases place a huge burden on families and on healthcare systems as they are a common cause of morbidity and cognitive impairment in older adults. The cost and societal impact of neurodegenerative disorders are increased by the disability they cause, and the high levels of daily, supervised care and assistance needed. Major unmet needs have been defined and strategies advanced to mitigate neurodegenerative diseases. Novel and multidisciplinary approaches are needed, as well as the strengthening and extension of existing capabilities across basic, clinical, social care and translational research, to achieve significant impact.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Checkoway H, Lundin JI, Kelada SN (2011) Neurodegenerative diseases. IARC Sci Publ 163:407–419
Alzheimer’s Association (2017) Alzheimer’s disease facts and figures. Alzheimers Dementia 13(4):325–373. https://doi.org/10.1016/j.jalz.2017.02.001
Gooch CL, Pracht E, Borenstein AR (2017) The burden of neurological disease in the United States: a summary report and call to action. Ann Neurol 81(4):479–484. https://doi.org/10.1002/ana.24897
Ortman JM, Velkoff VA, Hogan H. An aging nation: the older population in the United States. U.S. Department of Commerce Economics and Statistics Administration. https://www.census.gov/prod/2014pubs/p25-1140.pdf
Nichols E, Szoeke CE, Vollset SE, Abbasi N, Abd-Allah F, Abdela J et al (2019) Global, regional, and national burden of Alzheimer’s diseases and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 18(1):88–106. https://doi.org/10.1016/S1474-4422(18)30403-4
Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7(3):137–152. https://doi.org/10.1038/nrneurol.2011.2
Erkkinen MG, Kim MO, Geschwind MD (2018) Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol 10(4):a033118. https://doi.org/10.1101/cshperspect.a033118
Brookmeyer R, Gray S, Kawas C (1988) Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88(9):1337–1342. https://doi.org/10.2105/ajph.88.9.1337
https://www.scitecheuropa.eu/the-global-challenge-of-neurodegenerative-disorders/97957/
Hu CJ, Octave JN (2019) Editorial: Risk factors and outcome predicating biomarker of neurodegenerative diseases. Front Neurol 10:45. https://doi.org/10.3389/fneur.2019.00045
Hou Y, Dan X, Babber M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA (2019) Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 15(10):565–581. https://doi.org/10.1038/s41582-019-0244-7
Henegan P, Butt T, Crothers J, Waters B, Stommel E (2018) Exploring the potential risk factors of neurodegenerative disease in autopsy cases (P1.132). Neurology 90(15 Suppl):P1.132
Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B (2015) Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci 9:124. https://doi.org/10.3389/fncel.2015.00124
Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y (2009) Contribution of vascular risk factors to the progression of Alzheimer disease. Arch Neurol 66(3):343–348. https://doi.org/10.1001/archneur.66.3.343
Pagano G, Polychronis S, Wilson H, Giordano B, Ferrara N, Niccolini F, Politis M (2018) Diabetes mellitus and Parkinson disease. Neurology 90:e1654–e1662. https://doi.org/10.1212/WNL.0000000000005475
Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y (2009) Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66(3):343–348. https://doi.org/10.1001/archneur.66.3.343
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Peplow, P.V., Martinez, B., Gennarelli, T.A. (2022). Prevalence, Needs , Strategies , and Risk Factors for Neurodegenerative Diseases . In: Peplow, P.V., Martinez, B., Gennarelli, T.A. (eds) Neurodegenerative Diseases Biomarkers. Neuromethods, vol 173. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1712-0_1
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1712-0_1
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1711-3
Online ISBN: 978-1-0716-1712-0
eBook Packages: Springer Protocols